Energy & Endurance
5-Amino-1MQ
← Back to Library
Limited / unverified Limited / unverified Limited / unverified Metabolic Mitochondrial
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 50 mg
Dosing window: With Meals
Receptor / target: NNMT
Properties: Not stated
Pre-mixed: No
Unverified protocol notes
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Week 1 | 1mg 1x/day | Initiation dose. |
| Weeks 2 | 2mg 1x/day | First escalation. |
| Weeks 3-4 | 3mg 1x/day | Continued escalation. |
| Weeks 5-6 | 4mg 1x/day | Advanced phase. |
| Weeks 7-8 | 5mg 1x/day | Maximum protocol dose. |
Unverified protocol note; not label dosing unless graded otherwise on this page.
Alternative Titration 1: 4-Week Minimum Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 1mg 1x/day | Baseline entry protocol. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 2: 8-Week Minimum Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 1mg 1x/day | Standard initiation. |
| Weeks 5-8 | 2mg 1x/day | Step up for continued metabolic drive. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: Energy protocols are usually about mitochondrial or metabolic signaling. The logic is timing around meals/training, avoiding late-day stimulation, and watching sleep, glucose, blood pressure, and overtraining signals. Entry context: target (NNMT); route Subcutaneous; timing With Meals. Limited-evidence dosing tables are hypotheses, not recommendations.
Independent evidence
Independent safety notes: No independent approved-label regimen is listed for this entry. Dosing notes remain unverified.
Regulatory status: no approved label identified
Storage
No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (limited evidence)
- Active malignancy: NNMT inhibition increases intracellular NAD+ and SIRT1 activity, which in normal cells promotes health and longevity; in cancer cells, elevated NAD+ can fuel tumor metabolic demands and enhance DNA repair capacity that helps cancer cells evade treatment. Limited / unverified
- History of cancer: theoretical concern; assess risk-benefit individually. Limited / unverified
- Concurrent use with MAO inhibitors (MAOIs): 5-Amino-1MQ contains a quinolinium structure; potential pharmacological interaction with monoamine oxidase inhibition pathways is not characterized but warrants caution. Limited / unverified
- Known hypersensitivity to 5-Amino-1MQ or quinolinium-based compounds. Limited / unverified
- Pregnancy: no safety data; NAD+ pathway manipulation during fetal development is not established as safe. Limited / unverified
- Breastfeeding: no safety data. Limited / unverified
- Individuals with severely compromised renal or hepatic function: elimination and metabolism not characterized in organ impairment. Limited / unverified
- Pediatric use: no data. Limited / unverified
- Concurrent use with agents that also raise NAD+ (injectable NAD+, NMN, NR supplementation): the combined NAD+ elevation may be excessive in cancer-susceptible individuals; monitor accordingly in others. Limited / unverified
Side effects (limited evidence)
- Insomnia or sleep disruption: the most commonly reported side effect; increased cellular energy production and metabolic rate elevation interfere with sleep onset; mitigated by strict morning or with-meal dosing, never in the evening. Limited / unverified
- Mild anxiety and jitteriness: sympathomimetic-like stimulation from metabolic rate increase; not from direct adrenergic receptor agonism but from downstream mitochondrial activation; dose-dependent. Limited / unverified
- Injection site irritation: redness, soreness at the subcutaneous site; standard peptide injection response. Limited / unverified
- Mild headache: reported in early weeks; likely related to cellular metabolic shifts and NAD+ pathway activation. Limited / unverified
- Gastrointestinal discomfort: mild nausea or GI upset; more common if taken without food (hence the "With Meals" dosing requirement). Limited / unverified
- Transient fatigue in the post-dose window: paradoxical; as cells shift metabolic programs, a short window of fatigue may precede the sustained energy improvement. Limited / unverified
- Potential overstimulation of NAD+ production: theoretical; excessive SIRT1 activation could alter epigenetic regulation in ways not fully characterized in long-term human research. Limited / unverified
- No endocrine disruption: 5-Amino-1MQ has no known activity at hormone receptors; does not affect cortisol, testosterone, estrogen, or thyroid hormone pathways. Limited / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
TirzepatideMazdutideMOTS-cNAD+L-Carnitine (Injectable)SLU-PP-332CagriSema (Cagrilintide + Semaglutide)
Reported contraindicated combinations:
None listed.